Below is what BBY said.
Note the first sentence-- a SINGLE successfull CAR-T product is valued at 0.12/sh. That doesn't place any value at all on all the other patented and pending products that belong to PAB. Yet the market values the entire company and assets including ~ 1.7cps cash at 2.7c. On this I remain bewildered, perhaps I should be in a home for the bewildered.
Column 1 Column 2 0
We value a single successful CAR-T product at A$0.12/sh. Separately, PAB remains on track to commence the Phase 1/2 trial of PAT-SM6 in combination with Amgen’s Kyprolis in multiple myeloma patients before the end of CY14. We retain our Speculative Buy recommendation and price target of A$0.12/sh.
Patrys BBY Research - Target 12c, page-6
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $3.516K | 586.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500160 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 4889674 | 5 |
View Market Depth
| Last trade - 12.00pm 30/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |